The Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference Programs brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the world on cancer immunotherapy.
As the largest conference solely focused on cancer immunotherapy, the Annual Meeting & Pre-Conference Programs provides more than 3,500 international leaders from academia, regulatory and government agencies, as well as industry representatives with a multidisciplinary educational and interactive environment focused on improving outcomes for all cancer patients.
Learn from past delegates why you cannot miss the SITC Annual Meeting & Pre-Conference Programs in the following videos:
Thank you to all those who joined SITC November 8-12 in National Harbor, Md. for the 32nd Annual Meeting & Pre-Conference Programs!
As a benefit for attending the 32nd Annual Meeting and Pre-Conference Programs, SITC provides enduring materials free of charge for the specific programs for which attendees were registered. For those who did not attend SITC 2017, you can still receive access to these materials.
Click here to learn how you can obtain access to download presentations and video content from the 32nd Annual Meeting & Pre-Conference Programs.
The following are meeting reports published by SITC on programs hosted during the Annual Meeting.
Click here to visit our Annual Meeting's website for more content published from SITC 2017.
Looking for archived SITC Annual Meeting content? Visit past conference websites below:
The following are future scheduled dates and locations for the society's Annual Meeting & Pre-Conference Programs:
Nov. 7-11, 2018 at the Walter E. Washington Convention Center
Nov. 6-10, 2019 at the Gaylord National Hotel & Convention Center
National Harbor, Maryland
Nov. 11-15, 2020 at the Gaylord National Hotel & Convention Center
National Harbor, Maryland
Nov. 10-14, 2021 at the Walter E. Washington Convention Center
The majority of NSCLC patients do not still respond to PD-1/PD-L1 treatment. Chemotherapy is theorized to increase the release of tumor antigen resulting in increased response with immunotherapy. But cytotoxic chemotherapy can also destroy actively proliferating ...
more details in our latest news story: bit.ly/2CpnCWQ ------------------------------ Jade Parker Editor Future Science Group ------------------------------
Course Name: 6 th Annual Lung Cancer Symposium
Course Date: Friday, March 2, 2018
Course Co-Directors and Planners : Ralph Zinner, MD; Gregory Kane, MD; Judith Alberto, RPh; Rita Axelrod, MD; Stephanie Bork, MSN, CRNP; Nathaniel R. Evans III, ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com